Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CellCept mycophenolate mofetil: Phase IV data

In an open-label Phase IV trial in 1,645 renal transplant patients, a regimen of low-dose tacrolimus had significantly improved GFR, the primary endpoint, compared

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE